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The Himalayan Sherpas, a human population of Tibetan descent,
are highly adapted to life in the hypobaric hypoxia of high alti-
tude. Mechanisms involving enhanced tissue oxygen delivery in
comparison with Lowlander populations, have been postulated
to play a role in such adaptation. Whether differences in tissue
oxygen utilization (i.e. metabolic adaptation) underpin this adap-
tation is not however known. We sought to address this issue,
applying parallel molecular, biochemical, physiological and genetic
approaches to the study of Sherpas and native Lowlanders, stud-
ied before and during exposure to hypobaric hypoxia on a gradual
ascent to Mount Everest Base Camp (5,300 m). When compared
with Lowlanders, Sherpas demonstrated a lower capacity for fatty
acid oxidation in skeletal muscle biopsies, along with enhanced
efficiency of oxygen utilization, improved muscle energetics and
protection against oxidative stress. This in part appeared to be
related to a putatively advantageous allele for the PPARA gene,
which was enriched in the Sherpas compared with the Lowlanders.
Our findings suggest that metabolic adaptations underpin human
evolution to life at high altitude, and could impact upon our
understanding of human diseases in which hypoxia is a feature.
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Introduction
At high altitude, low barometric pressure is accompanied by a
fall in the partial pressure of inspired O2, resulting in hypobaric
hypoxia. The cellular response to hypoxia is orchestrated by the
Hypoxia Inducible Factor (HIF) transcription factors, with HIF-
1α and HIF-2α respectively mediating responses to short-term
andmore sustained hypoxia (1). In normoxia, prolyl-hydroxylases
target HIFα subunits for destruction (2). Under low O2 partial
pressures, however, HIF-1α/HIF-2α are stabilized and dimer-
ize with the nuclear HIF-1β subunit. This dimer interacts with
hypoxia-response elements in promoter regions to increase ex-
pression of specific genes, e.g. EPO (encoding erythropoietin)
and VEGFA (vascular endothelial growth factor A) (3).
The Tibetan Plateau has an average altitude of some 4,500
m. Humans were first present on the Plateau ∼30,000 years ago,
with the earliest permanent settlements appearing 6-9,000 years
ago (4) – a period sufficient to drive the natural selection of
genetic variants (and associated features) favouring survival and
performance in sustained hypoxia (5, 6). Evidence supports the
selection of genetic variants encoding components of the hypoxia-
inducible factor (HIF) pathway, such as EPAS1 (encoding HIF-
2α) (7) and EGLN1 (prolyl-hydroxylase-2, PHD2) (8) in Tibetan
populations. One population, the Sherpas, migrated from Tibet
to eastern Nepal∼500 years ago and exhibit remarkable physical
performance at extreme altitude (9).
Whilst the human adaptive response to hypoxia is incom-
pletely understood,mitigation against the fall in convectiveO2 de-
livery plays an important role. In Lowlanders, increased ventila-
tion and cardiac output, and the production of more O2-carrying
red blood cells help to sustain O2 delivery and content (10, 11).
Likewise, exhaled concentrations of nitric oxide (NO), a key
regulator of blood flow, are higher in Tibetans than Lowlanders
(12), as are circulating NO metabolites and limb blood flow (13).
The rise in red cell mass in response to hypobaric hypoxia is not as
great in Tibetans as in Lowlanders, however (14, 15), suggesting
that adaptation involves more than just increased O2 delivery.
In fact, acclimatization also involves alterations in O2 use. In
Lowlander muscle, mitochondrial density declines with sustained
exposure to extreme altitude (16-18), whilst exposure to more
moderate high altitude is associated with a reprogramming of
muscle metabolism (19) even without altered mitochondrial den-
sity (20), including downregulation of electron transfer complexes
(19) and tricarboxylic acid (TCA) cycle enzymes (21), loss of fatty
acid oxidation (FAO) capacity (19, 20) and improved oxidative
phosphorylation coupling efficiency (20). Sherpas have lower
muscle mitochondrial densities than unacclimatized Lowlanders
(22), but little is known of their metabolic adaptation to hypoxia,
or any genetic selection which might underpin it. A role has been
suggested for peroxisome proliferator-activated receptor alpha
(PPARα), a transcriptional regulator of FAO in liver, heart and
muscle. HIF downregulates PPARα in some tissues (23), whilst
there is evidence for selection of variants in its encoding gene
(PPARA) in some Tibetan subgroups (8, 24). We hypothesized
that metabolic adaptation, and PPARα in particular, play a cen-
tral role in the Sherpa adaptation to hypobaric hypoxia.
Results and Discussion
Selection of PPARA Variants in Sherpas
Lowlander and Sherpa subjects were participants of the re-
search expedition, Xtreme Everest 2 (25). The Lowlanders com-
prised 10 investigators selected to operate the Everest Base Camp
(EBC) laboratory. Sherpas (n = 15) were a sex-matched (73%
Significance
A relative fall in tissue oxygen levels (hypoxia) is a common
feature of many human diseases including heart failure, lung
diseases, anemia and many cancers, and can compromise nor-
mal cellular function. Hypoxia also occurs in healthy humans
at high altitude due to low barometric pressures. Human
populations resident at high altitude in the Himalayas have
evolved mechanisms that allow them to survive and perform,
including adaptations that preserve oxygen delivery to the
tissues. Here we studied one such population, the Sherpas, and
found metabolic adaptations, underpinned by genetic differ-
ences, which allow their tissues to use oxygen more efficiently,
thereby conserving muscle energy levels at high altitude, and
possibly contributing to the superior performance of elite
climbing Sherpas at extreme altitudes.











































































































































Fig. 1. Subject genetics, ascent profile, arterial blood O2 saturation, muscle
hypoxia and circulating NO metabolites. A) Genotypes of Lowlanders and
Sherpas at 3 PPARA SNPs - subjects homozygous for the putatively advanta-
geous allele in black, heterozygous subjects in gray and subjects homozygous
for the non-advantageous allele in white (digits in segments refer to number
of subjects with genotype); B)Ascent profile including timing of biopsies; C)
Arterial hemoglobin-O2 saturations; D) Muscle VEGFA expression, and E-H)
plasma nitrogen oxides in Lowlanders (L) and Sherpas (S) at baseline (B) and
early (A1) and late (A2) altitude. Mean ± SEM (n = 4-15). †P ≤ 0.05; †††P ≤
0.001 B vs A1 within cohort. ΔP ≤ 0.05 A1 vs A2 within cohort.
male, cf. 70% in Lowlanders) and age-matched (26.8 ± 1.2 yr, cf.
28.0 ± 1.6 yr in Lowlanders) group living in Kathmandu and the
Fig. 2. Fatty acid oxidation and regulation in muscle. A)PPARA expression;
B) CPT1B expression; C) HADH activity; D) Oxidative phosphorylation with
octanoylcarnitine&malate (FAOP); E) Total carnitine; F)Long chain/total car-
nitine ratio in Lowlanders and Sherpas. Gene expression and carnitine levels
are expressed relative to Lowlanders at baseline. Mean ± SEM (n = 6-13). *P
≤ 0.05; **P ≤ 0.01 Lowlanders vs Sherpas at baseline. †P ≤ 0.05 baseline vs
altitude within cohort.
Solukhumbu and Rolwaling valleys. No subject ascended higher
than 4,200 m in the 3 months preceding the trek, nor above
2,500 m in the preceding 3 weeks. In addition, Sherpas presented
evidence of sole Sherpa ancestry for 2 generations (i.e. 4 Sherpa
grandparents). The frequency of putatively advantageous PPARA
alleles (8) was higher in Sherpas than Lowlanders (Fig. 1A; Table
S1), with genotype frequencies of the cohorts being significantly
different at 2 single nucleotide polymorphisms (SNPs), rs6520015
and rs7292407 (P = 0.0091), though not rs9627403. This reflected
patterns reported in some other Tibetan groups (26).
Muscle Hypoxia and Circulating NO Metabolites
Baseline testing, including blood sampling, muscle biopsy
sampling, high-resolution respirometry of permeabilized mus-
cle fibers and oral glucose tolerance tests (OGTT) took place
in London (35 m) for Lowlanders and Kathmandu (1,300 m)
for Sherpas (25). All subjects then followed an identical as-
cent (Fig. 1B) from Kathmandu to EBC (5,300 m) whereupon
further testing took place at an early timepoint (A1; 15-20 d
post-departure for Lowlanders, 11-12 d for Sherpas), and a late
timepoint (A2; 54-59 d post-departure) for Lowlanders only. At
the time of sampling, both groups had passed through the acute
phase of hypoxic exposure (<24 h) (1) and had been sufficiently
exposed to chronic hypoxia for acclimatization to have occurred.
Indeed, arterial hemoglobin-O2 saturations were similarly low
in both groups (Fig. 1C), whilst muscle expression of the HIF-
target VEGFA increased in all subjects (Fig. 1D), indicating a
molecular response to hypoxia. Following measurements at A1,
the Lowlanders remained at EBC for 2 months to carry out
research, presenting an opportunity to collect data pertaining











































































































































Fig. 3. TCA intermediates and activity in muscle. A) Citrate synthase activity
and B-I) TCA cycle intermediates in Lowlanders and Sherpas. Metabolite
levels are expressed relative to Lowlanders at baseline. Mean ± SEM (n =
7-14). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 Lowlanders vs Sherpas at baseline.
†P ≤ 0.05; ††P ≤ 0.01; baseline vs altitude within cohort.
expression was no longer elevated by this timepoint, suggesting
further acclimatization had occurred.
Fig. 4. Mitochondrial oxygen consumption, efficiency and uncoupling
protein expression. A) N-OXPHOS (GMP), B) S-ETS capacity (SE) and C) NS-
OXPHOS capacity (GMSP) in permeabilized muscle fibers from Lowlanders
and Sherpas. D) Octanoylcarnitine&malate-supported LEAK (FAOL) and E)
OXPHOS coupling efficiency. F) Muscle UCP3 expression relative to Lowlan-
ders at baseline. Mean ± SEM (n = 7-11).**P ≤ 0.01; ***P ≤ 0.001 Lowlander vs
Sherpas at baseline. †P ≤ 0.05; ††P ≤ 0.01 baseline vs altitude within cohort.
ΔP ≤ 0.05; ΔΔP ≤ 0.01 altitude 1 vs 2 within cohort.
To our surprise, there were no differences in circulating N-
nitrosamine (RNNO), S-nitrosothiol (RSNO), nitrate (NO3-) or
nitrite (NO2-) concentrations between Lowlanders and Sherpas
at baseline (Fig. 1E-H). In Lowlanders, a transient increase in
plasma RNNO levels occurred upon arrival at EBC (P < 0.05)
but disappeared by the later timepoint (Fig. 1E). In Sherpas,
plasma nitrate levels fell at altitude (P <0.05; Fig. 1G) and nitrite
levels increased (P < 0.05; Fig. 1H), whilst in Lowlanders nitrite
levels fell by the later timepoint (P < 0.05). The absence of large
differences in NO metabolites between the groups at baseline or
at altitude, suggested an adaptive phenotype in Sherpas that is
distinct from other Tibetan highlanders (13).
Lower Fatty Acid Oxidation Capacity in Sherpas
Skeletal muscle biopsies revealed marked differences in gene
expression and FAO capacity between Sherpas and Lowlanders.
Expression of PPARA mRNA was 48% lower in Sherpas than
Lowlanders (P < 0.05; Fig. 2A), thus the putatively advantageous
PPARA allele is associated with diminished expression. Corre-
spondingly, expression of the PPARα target CPT1B was 32%
lower in Sherpas at baseline compared with Lowlanders (P <
0.05; Fig. 2B). The PPARA gene contains 139 SNPs. rs6520015 is
one of the tagging SNPs reported by Simonson et al (8), however
it appears to be a non-coding variant. It is thus uncertain whether
the SNP itself affects transcriptional regulation, or whether it tags
a functional variant elsewhere, modifying expression or mRNA
stability. Ascent to EBC did not alter PPARA expression in either











































































































































Fig. 5. Muscle glycolysis and blood glucose homeostasis. A)Hexokinase
andB)Lactate dehydrogenase activity. C) Fasting blood glucose and D) glu-
cose clearance during OGTT. E) Total muscle glycolytic intermediates relative
to Lowlanders at baseline. Mean ± SEM (n = 5-14). *P ≤ 0.05 Lowlanders vs
Sherpas at baseline. †P ≤ 0.05; ††P ≤ 0.01; †††P ≤ 0.001 baseline vs altitude
within cohort.
Lowlanders (P < 0.05) but did not decrease further in Sherpas.
This suggests that the Lowlander response to hypoxia involves
decreased PPARα transcriptional activity without changes in
PPARA expression, similar to hypoxic rat skeletal muscle (27).
Gene expression changes do not necessarily reflect pro-
tein levels or activity, therefore we measured activity of the β-
oxidation enzyme 3-hydroxyacyl-CoA dehydrogenase (HADH),
finding it to be 27% lower in Sherpas than Lowlanders at base-
line (P < 0.05), and not changing in either group following
ascent (Fig. 2C). Moreover, fatty acid oxidative phosphorylation
capacity (FAOP) was measured as the oxygen flux in saponin-
permeabilized muscle fibers with octanoylcarnitine, malate and
ADP, using high-resolution respirometry (28). FAOP was 24%
lower in Sherpas than Lowlanders at baseline (P < 0.01), and did
not change in either group following ascent (Fig. 2D, Fig. S1). Ex
vivo measurements may be particular to assay conditions used,
therefore we also measured muscle metabolite levels to indicate
changes in metabolism in vivo. Total carnitine concentrations
decreased in Lowlanders with time spent at EBC (P < 0.05),
though were not significantly different to those in Sherpas at
baseline (Fig. 2E). The ratio of long chain acylcarnitines to total
carnitines, however, increased in Lowlanders with time at altitude
(P<0.05; Fig. 2F), suggesting incomplete FAO results in accumu-
Fig. 6. Muscle energetics and oxidative stress. A)Phosphocreatine, B) ATP,
C)Oxidized/reduced glutathione (GSSG/GSH) and D) Sulfoxide/total methio-
nine (MetSO/Met), all expressed relative to Lowlanders at baseline. Mean ±
SEM (n = 8-14). ††P ≤ 0.01; †††P ≤ 0.001 baseline vs altitude within cohort.
ΔP ≤ 0.05 altitude 1 vs 2 within cohort.
lation of potentially-harmful lipid intermediates (29). In Sherpa
muscle, however, the long chain acylcarnitine to total carnitine
ratio was lower than in Lowlanders at baseline (P<0.05), perhaps
resulting from lower expression of CPT-1. In further contrast with
Lowlanders, the long chain acylcarnitine to total carnitine ratio
remained low in Sherpa muscle at altitude.
TCA Cycle Regulation at High Altitude
We therefore sought to understandwhether there were differ-
ences between the populations in other aspects of mitochondrial
metabolism. TheTCA cycle enzyme citrate synthase (CS) is a can-
didate marker of mitochondrial content in human muscle (30).
At baseline, Sherpas had a 26% lower muscle CS activity than
Lowlanders (P < 0.05; Fig. 3A), in agreement with findings of
17-33% lower mitochondrial volume density in Sherpa vastus lat-
eralis compared with Lowlanders (22). In accordance with lower
CS activity, concentrations of 6- and 5-carbon intermediates
downstream of CS (citrate, aconitate, isocitrate, α-ketoglutarate)
were lower in Sherpas than Lowlanders (P < 0.001). However,
concentrations of 4-carbon intermediates (succinate, fumarate,
malate, oxaloacetate) were not different (Fig 3B-I). This suggests
an alternative strategy to supply the TCA cycle with succinate.
Intriguingly, recent analysis of a large SNP dataset from low
and high altitude-adapted populations in the Americas and Asia
(31) aimed to identify pathways of convergent evolution, and
highlighted fatty acid ω-oxidation as the most significant cluster
of overlapping gene sets between high altitude groups (32). ω-
oxidation, is normally a minor pathway in vertebrates, becoming
more important when β-oxidation is defective (33), and through
successive cycles oxidizes fatty acids to adipate and succinate
in the endoplasmic reticulum, after which succinate enters the
mitochondria with anaplerotic regulation of the TCA cycle (34).
Upon ascent to altitude, 6- and 5-carbon TCA cycle interme-
diates increased in Sherpa muscle (P < 0.05; Fig. 3B-E), suggest-
ing improved coupling of intermediary metabolism, TCA cycle
and oxidative phosphorylation. In Lowlanders, however, citrate,
aconitate and isocitrate decreased at altitude (P < 0.05; Fig. 3B-
D), despite no significant change in CS activity, perhaps reflecting
impairments upstream. Interestingly, α-ketoglutarate concentra-
tions weremaintained in Lowlanders at altitude (Fig. 3E), despite
decreased succinate downstream, which could be explained by











































































































































dehydrogenase, reported previously in Lowlanders following an
identical ascent to EBC (21). α-ketoglutarate plays regulatory
roles in hypoxia, including a suppression ofHIF stabilization (35),
but also supporting glutathione synthesis (36). Taken together,
these results indicate different TCA cycle regulation in Sherpas
and Lowlanders. The replete TCA cycle of Sherpas at altitude
contrasts sharply with the depletion of TCA cycle intermediates
in Lowlanders, and suggests a coupling of theTCAcycle in Sherpa
muscle to their distinct intermediary substrate metabolism.
Greater Mitochondrial Coupling Efficiency in Sherpas
To further understand whether mitochondrial function dif-
fers between Sherpas and Lowlanders, we used high-resolution
respirometry, to probe electron transfer system (ETS) capacity
and coupling efficiency in permeabilized muscle fibers. At base-
line, there was no significant difference between the two groups
in OXPHOS or ETS capacities with either malate and glutamate
(N-pathway through Complex I) or succinate as substrates (S-
pathway through Complex II; Fig. 4A,B; Fig. S2), but Sherpas had
a lower OXPHOS capacity with malate, glutamate and succinate
combined to reconstitute TCA cycle function (NS-pathway; P
< 0.01; Fig. 4C). There were no early changes in either group
upon ascent. By the later timepoint however, succinate-linked
respiration had fallen in Lowlanders (P < 0.05), consistent with
previous findings of decreased succinate dehydrogenase (Com-
plex II) levels in subjects with sustained exposure >5,300 m (21).
In addition, we measured muscle fiber respiration in the ab-
sence of ADP (LEAK), i.e. O2 consumption without ADP phos-
phorylation. Expressing LEAK relative to OXPHOS capacity, it
is possible to calculate OXPHOS coupling efficiency (37, 38). At
baseline, Sherpa muscle mitochondria had lower LEAK respira-
tion and greater coupling efficiency than Lowlander mitochon-
dria (P < 0.001; Fig. 4D,E), indicating more efficient use of O2.
Upon ascent to EBC and with sustained time at altitude, LEAK
decreased in Lowlanders (P < 0.01), though it remained higher
than in Sherpas (Fig. 4D), and coupling efficiency improved (P
< 0.05; Fig. 4E). In Sherpas at altitude, LEAK did not change
although coupling efficiency decreased (P < 0.01). One possible
explanation for these differences in coupling efficiency might be
the altered expression of uncoupling protein 3 (UCP3). UCP3
is a transcriptional target of PPARα and lower UCP3 levels at
altitudemight improve the efficiency ofO2 utilization. In previous
studies, however, muscle UCP3 expression increased with acute
hypoxia (17, 39), which may offer some protective benefit con-
sidering its possible role as an antioxidant (39). Notably though,
UCP3 levels decreased with more sustained exposure to extreme
altitude (17). Here, UCP3 was upregulated in Sherpas at altitude
in association with decreased coupling efficiency (P < 0.05; Fig.
4F). However, UCP3 expression also increased in Lowlanders in
the short-term (P < 0.01) in whom there was decreased LEAK
respiration. Moreover, UCP3 expression returned to baseline in
Lowlanders with longer-term exposure with no further change in
LEAK respiration. Overall, our results indicate that Sherpa mus-
cle mitochondria are characterized by a lower OXPHOS capacity
and greater, albeit declining, efficiency, whilst in Lowlanders
OXPHOS efficiency improved with acclimatization.
Glycolysis and Glucose Metabolism
Next we investigated the capacity to derive cellular energy
via glycolysis, which is increased in hypoxic cells (40), as this may
allowATP levels to bemaintainedwhenO2 is limited. Hexokinase
activity was the same in both groups at baseline, and did not
change at altitude (Fig. 5A), however lactate dehydrogenase
(LDH) activity was 48% higher in Sherpa muscle than in Lowlan-
ders (P < 0.05), indicating greater capacity for anaerobic lactate
production (Fig. 5B). Fasting blood glucose was the same in
Sherpas and Lowlanders at baseline, and decreased upon ascent
in Lowlanders (P < 0.01; Fig. 5C), who also showed faster clear-
ance of glucose during an OGTT (P < 0.001; Fig. 5D) in agree-
ment with previous reports (41). In Sherpas, however, there was
no indication of altered glucose homeostasis. Meanwhile, over
time at altitude glycolytic intermediates increased in Lowlander
muscle (Fig. 5E) with increased glucose-6-phosphate/fructose-
6-phosphate and 2-phosphoglycerate/3-phosphoglycerate (Table
S2). In contrast, total glycolytic intermediates did not change in
Sherpamuscle, although 2-phosphoglycerate/3-phosphoglycerate
decreased. These findings, might to some extent be explained
by altered HIF activities. Many genes encoding glycolytic en-
zymes are upregulated by HIF-1 (42), whilst hypoglycemia is
seen in Chuvash polycythemia, an autosomal recessive disorder
in which HIF degradation is impaired (43). Taken together, our
findings suggest an increased reliance on glucose by Lowlanders
under resting conditions at altitude compared with Sherpas, but
a greater capacity for lactate production in Sherpas which may
prove effective upon exertion.
Energetics and Oxidative Stress
Finally, to understand the implications of Sherpa metabolic
adaptation we investigated muscle energetics and redox home-
ostasis. Lowlanders at altitude showed progressive loss of muscle
phosphocreatine (PCr; P < 0.001; Fig. 6A), indicating a loss of
energetic reserve, which may relate to downregulation of mus-
cle creatine kinase, as reported previously (21). By contrast, in
Sherpa muscle, PCr increased at altitude (P < 0.01). Similarly,
Sherpa muscle ATP levels, which were lower than in Lowlan-
ders at baseline (P < 0.05), increased at altitude (P < 0.001;
Fig. 6B), illustrating that Sherpa metabolism is better suited
to maintaining muscle energetics at altitude than Lowlander
metabolism in either the short-term or following acclimatiza-
tion. Moreover, with short-term exposure, markers of oxidative
stress (reduced/oxidized glutathione and methionine sulfoxide)
increased in Lowlander muscle, but not Sherpa muscle (Fig.
6C,D), indicating superior redox homeostasis in the Sherpas.
Antioxidant protection may represent another outcome of con-
vergent evolution, having been reported in Andean subjects in
associationwith protection of fetal growth (44), whilst glutathione
levels are raised in Chuvash polycythemia suggesting a possible
role for HIF activation (45).
Conclusions
It has long been suspected that Sherpa people are better adapted
to life at high altitude than Lowlanders (46). Recent findings have
suggested a genetic basis to adaptation in populations around
the world (6), and here we show that Sherpas have a metabolic
adaptation associated with improved muscle energetics and pro-
tection against oxidative stress. Genetic selection on the PPARA
gene is associated with decreased expression, and thus lower
fatty acid β-oxidation and improved mitochondrial coupling com-
pared with Lowlanders, with a possible compensatory increase in
fatty acid ω-oxidation. Sherpas also have a greater capacity for
lactate production. With acclimatization to altitude, Lowlanders
accumulate potentially-harmful lipid intermediates in muscle as
a result of incomplete β-oxidation, alongside depletion of TCA
cycle intermediates, accumulation of glycolytic intermediates, a
loss of PCr despite improved mitochondrial coupling, and a tran-
sient increase in oxidative stress markers. In Sherpas, however,
there are remarkably few changes in intermediary metabolism at
altitude, but increasedTCA cycle intermediates and PCr andATP
levels, with no sign of oxidative stress.
Genetic selection, by definition, requires an increased likeli-
hood of advantageous gene variants being passed on to offspring.
This might occur if the disadvantageous variant is associated
with poorer survival to reproductive age and beyond, including
greater fetal/neonatal mortality. Evidence supports precisely such
effects with fetal growth at altitude being poorer in Lowlander
populations than many native highlanders (47), including Ti-











































































































































survival through childhood or fecundity/fertility in the hypoxic
environment. We cannot speculate on the mechanism by which
PPARA variants prove advantageous, however PPAR isoforms are
expressed in the placenta (50) and influence female reproductive
function (51). It would be of interest to seek association of the
PPARA variants with birth weight and measures of placentation
in high altitude natives and Lowlanders exposed to hypoxia.
Our findings suggest a metabolic basis to Sherpa adaptation,
which may permit the population to survive and perform at
high altitude. Such adaptations may also underpin the superior
performance of elite climbing Sherpas at extreme high altitude.
Materials and Methods
Subjects were selected from the participants of Xtreme Everest 2 (25).
All Lowlanders were born and lived below 1,000 m, not descended from
a high altitude-dwelling population and of European (Caucasian) origin.
Subjects gave written consent, and underwent medical screening. All pro-
tocols were approved by UCL Research Ethics Committee and Nepal Health
Research Council. Vastus lateralis biopsies were taken from the mid-thigh,
muscle fibers prepared for respirometry (28) and respiration measured using
substrate-uncoupler-inhibitor titrations (Tables S3, S4). Enzyme activities
were assayed as described (27). RNA was extracted and Taqman® assays
used to analyse gene expression (Table S5). For metabolite analysis, a
methanol/chloroform extraction (52) was followed by liquid chromatogra-
phy mass spectrometry (LC-MS). OGTTs were carried out on fasted subjects
on the day after biopsies. Blood plasma NO metabolites were quantified as
described (53). Genomic DNA was isolated from whole blood and PPARA SNPs
genotyped using TaqMan® for allelic discrimination (Applied Biosystems, UK;
Table S1). To compare cohorts at baseline, an unpaired two-tailed Student’s t-
test was used (significance at P ≤ 0.05). Genotype frequencies were compared
using a Chi-squared test. To assess the effects of altitude, a one-way ANOVA
with repeated measures was used. Post-hoc pairwise comparisons were
carried out with a Tukey correction.
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